Simplified Summary
SLU-PP-332 functions as an agonist at ERRα and ERRγ, constitutively active transcriptional regulators of mitochondrial and oxidative metabolic gene networks. Preclinical research has used this compound to investigate how pharmacological activation of ERR signalling influences mitochondrial biogenesis, skeletal muscle oxidative capacity, and energy metabolism in animal models.
Key Findings Reported in Preclinical Models
- Upregulation of mitochondrial biogenesis markers in skeletal muscle including TFAM and cytochrome c oxidase subunits.
- Enhanced aerobic exercise capacity in preclinical rodent model treadmill and voluntary wheel running experiments.
- Modulation of skeletal muscle fibre type composition markers suggesting a shift toward oxidative fibre type gene expression profiles.
- Activation of ERRα and ERRγ target gene networks characterised through RNA sequencing analyses of animal model muscle tissue.
- Intersection with PGC-1α signalling pathways, characterising how SLU-PP-332-mediated ERR activation relates to the master regulator of mitochondrial biogenesis.
Introduction
ERRα and ERRγ are orphan nuclear receptors that regulate gene networks governing mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation in metabolically active tissues. They are constitutively active and regulated through coactivator interactions, most notably with PGC-1α. Preclinical research has identified them as central transcriptional mediators of the metabolic adaptations associated with endurance exercise, motivating interest in ERR agonists as exercise mimetic research tools.
Research Applications
- Mitochondrial biogenesis research in skeletal muscle cell culture and animal model systems.
- Exercise mimetic biology research examining whether ERR agonism recapitulates aspects of endurance exercise-induced muscle remodelling in sedentary animal cohorts.
- ERR nuclear receptor pharmacology studies using SLU-PP-332 as a chemical probe.
- Energy metabolism and metabolic flexibility research examining whole-body substrate utilisation under sustained ERRα/ERRγ pathway activation.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.